Patents by Inventor Ulrich Demuth

Ulrich Demuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Compounds of unstable DP IV-inhibitors

Patent number: 7053055

Abstract: Novel compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.

Type: Grant

Filed: December 21, 2000

Date of Patent: May 30, 2006

Assignee: Prosidion Ltd.

Inventors: Hans-Ulrich Demuth, Jorn Schmidt, Torsten Hoffmann, Konrad Glund
Novel compounds for the treatment of neurological disorders

Publication number: 20060100253

Abstract: The present invention relates to novel inhibitors of prolyl endopeptidase of formula 1 W—KCONH—X—CON—Y—CO—Z ??(1) wherein K, W, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.

Type: Application

Filed: November 30, 2005

Publication date: May 11, 2006

Inventors: Andre Niestroj, Ulrich Heiser, Ingo Schulz, Jens-Ulrich Rahfeld, Joachim Baer, Hans-Ulrich Demuth
Plug connector arrangement

Patent number: 7025610

Abstract: An electrical connector arrangement having a first connector which is arranged in a housing and may be brought into an electrical connection with a mating connector by the actuation of an actuation lever arranged movably on the first connector. The actuation lever being movable between a free position in which the two connectors are not fully mated and a coupled position in which the two connectors are fully mated. A portion of the actuation lever is disposed between the first connector and the housing with a clamping projection on the lever that is in engagement with a mating clamping projection on the housing when the actuation lever is in the coupled position.

Type: Grant

Filed: April 13, 2004

Date of Patent: April 11, 2006

Assignee: Tyco Electronics AMP GmbH

Inventor: Ulrich Demuth
Novel inhibitors of dipeptidyl peptidase I

Publication number: 20050233978

Abstract: The present invention relates to new compounds that act as specific inhibitors of the cysteine protease dipeptidyl peptidase I (DP I). Those compounds are represented by the general formula and the pharmaceutical salts thereof, in which R is an acyl-residue including urethane and peptide, or a branched or unbranched C1-C9 alkyl chain, a branched or unbranched C2-C9 alkenyl chain, a branched or unbranched C2-C9 alkynyl chain, a C3-C9 cycloalkyl, C4-C9 carbocyclic, C5-C14 aryl, C3-C9 heteroaryl, C3-C9 heterocyclic, all of the above residues may be optionally substituted, or is H, AS is an amino acid or a peptide mimetic thereof. The amino acid is peptide bound with R and R? is a branched or unbranched C1-C9 alkyl chain, a branched or unbranched C2-C9 alkenyl chain, a branched or unbranched.

Type: Application

Filed: November 24, 2004

Publication date: October 20, 2005

Inventors: Andre Niestroj, Ulrich Heiser, Hans-Ulrich Demuth
Method for the improvement of islet signaling in diabetes mellitus and for its prevention

Publication number: 20050222221

Abstract: The present invention discloses a method for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic ?-cells and to cause differentiation of pancreatic epithelial cells into insulin producing ?-cells. Oral administration a DP IV inhibitor causes the active form of GLP-1 to be preserved longer under physiological conditions. The extended presence of GLP-1, in particular in the pancreatic tissue facilitates differentiation and regeneration of the ?-cells already present that are in need of repair. These repaired insulin producing cells can contribute to the correction and maintenance of normal physiological glycemic levels.

Type: Application

Filed: October 1, 2003

Publication date: October 6, 2005

Inventors: Hans-Ulrich Demuth, Konrad Glund
Novel inhibitors of glutaminyl cyclase

Publication number: 20050215573

Abstract: The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.

Type: Application

Filed: February 4, 2005

Publication date: September 29, 2005

Inventors: Stephan Schilling, Mirko Buchholz, Andre Niestroj, Ulrich Heiser, Hans-Ulrich Demuth
Effectors of dipeptidyl peptidase IV for topical use

Patent number: 6949515

Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.

Type: Grant

Filed: February 22, 2002

Date of Patent: September 27, 2005

Assignee: Probiodrug AG

Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
Effectors of dipeptidyl peptidase IV for topical use

Publication number: 20050209159

Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.

Type: Application

Filed: March 1, 2005

Publication date: September 22, 2005

Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
Glutaminyl based DPIV inhibitors

Patent number: 6946480

Abstract: The present invention provides compounds of the formula: wherein X?CH2 or S or pharmaceutical acceptable salts thereof useful for treating conditions mediated by DPIV or DPIV-like enzymes, such as arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases.

Type: Grant

Filed: September 16, 2002

Date of Patent: September 20, 2005

Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Ulrich Heiser
Novel effectors of dipeptidyl peptidase IV

Publication number: 20050203030

Abstract: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.

Type: Application

Filed: December 2, 2003

Publication date: September 15, 2005

Inventors: Hans-Ulrich Demuth, Konrad Glund, Dagmar Schlenzig, Susanne Kruber
Secondary binding site of dipeptidyl peptidase IV (DPIV)

Publication number: 20050176622

Abstract: The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

Type: Application

Filed: September 18, 2003

Publication date: August 11, 2005

Inventors: Kerstin Kuhn-Wache, Joachim Bar, Hans-Ulrich Demuth, Torsten Hoffmann, Ulrich Heiser, Wolfgang Brandt
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents

Publication number: 20050171025

Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

Type: Application

Filed: March 30, 2005

Publication date: August 4, 2005

Inventors: Stephan von Hoersten, Hans-Ulrich Demuth, Torsten Hoffmann
Combinations useful for the treatment of neuronal disorders

Publication number: 20050171112

Abstract: The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof.

Type: Application

Filed: December 2, 2004

Publication date: August 4, 2005

Inventors: Ingo Schulz, Stephan Schilling, Andre Niestroj, Ulrich Heiser, Hans-Ulrich Demuth, Steffen Rossner
Combinations useful for the treatment of neuronal disorders

Publication number: 20050137142

Abstract: The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof.

Type: Application

Filed: October 29, 2004

Publication date: June 23, 2005

Inventors: Ingo Schulz, Stephan Schilling, Andre Niestroj, Hans-Ulrich Demuth, Steffen Rossner
Novel analogues of glucose-dependent insulinotropic polypeptide

Publication number: 20050137135

Abstract: The present invention relates to novel C-terminal truncated fragments and novel N-terminal modified analogues of gastric inhibitory polypeptide as well as various GIP analogues with a reduced peptide bond or alterations of the amino acids close to the dipeptidyl peptidase IV (DPIV)-specific cleavage site providing improved DPIV-resistance and prolonged half-life. Further the invention relates to novel analogs with different linkers between potential receptor binding sites of GIP. The compounds of the present invention and their pharmaceutically acceptable salts are useful in treating GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.

Type: Application

Filed: January 25, 2005

Publication date: June 23, 2005

Inventors: Simon Hinke, Susanne Manhart, Jan Ehses, Christopher McIntosh, Hans-Ulrich Demuth, Raymond Pederson
Use of dipeptidyl peptidase IV effectors for normalizing the blood glucose level in mammals

Publication number: 20050107309

Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.

Type: Application

Filed: December 22, 2004

Publication date: May 19, 2005

Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert Pauly, Christopher McIntosh, Ray Pederson
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels

Publication number: 20050107308

Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.

Type: Application

Filed: October 21, 2004

Publication date: May 19, 2005

Inventors: Andrew Pospisilik, Hans-Ulrich Demuth, Kourad Glund, Matthias Hoffmann, Christopher McIntosh, Ray Pederson
Methods for improving islet signaling in diabetes mellitus and for its prevention

Patent number: 6890905

Abstract: The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic ?-cells, to cause differentiation of pancreatic epithelial cells into insulin producing ?-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the ?-cells already present that are in need of repair.

Type: Grant

Filed: August 9, 2002

Date of Patent: May 10, 2005

Assignee: Prosidion Limited

Inventors: Hans-Ulrich Demuth, Konrad Glund, Andrew J. Pospisilik, Kerstin Kuehn-Wache
Use of effectors of glutaminyl and glutamate cyclases

Publication number: 20050058635

Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screeing for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.

Type: Application

Filed: May 5, 2004

Publication date: March 17, 2005

Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre Niestroj, Stephan Schilling, Ulrich Heiser
Plug connector arrangement

Publication number: 20050026484

Abstract: An electrical connector arrangement having a first connector which is arranged in a housing and may be brought into an electrical connection with a mating connector by the actuation of an actuation lever arranged movably on the first connector. The actuation lever being movable between a free position in which the two connectors are not fully mated and a coupled position in which the two connectors are fully mated. A portion of the actuation lever is disposed between the first connector and the housing with a clamping projection on the lever that is in engagement with a mating clamping projection on the housing when the actuation lever is in the coupled position.

Type: Application

Filed: April 13, 2004

Publication date: February 3, 2005

Inventor: Ulrich Demuth

prev … 4 5 6 7 8 9 10 11 next